1. June 01, 2007
Endophore Confidential
Page 1 of 2
ENDOPHORE™, INC. - EXECUTIVE SUMMARY
Company
Endophore™, Inc. is a conceptual-stage company pioneering the development of resonant
nanostructures for biomedical applications. Our mission is to develop novel tools and methods
to identify and eradicate disease without adverse side-effects. The name Endophore is derived
from endo (inside) and phore (carrier).
Technology
Endophore is developing resonant nanostructures based on a patent application titled
"Resonant Nanostructures and Methods of Use". The patent is currently in the national review
phase and can be found at: http://www.google.com/patents?id=WKeAAAAAEBAJ.
Resonant nanostructures (RNSs) are typically nano-scale structures engineered to resonate at
specific frequencies in response to external stimulus (such as acoustic and electromagnetic
forces). They can be composed of biocompatible materials and engineered and functionalized
to target specific cells and/or molecules, in vivo and in vitro, to elicit a desired effect through
drug delivery, energy release, and/or other means.
Problems Addressed
Resonant nanostructures are the foundation of a new class of tools and methods to enable
temporally-controlled, targeted diagnosis and treatment of disease. The technology can also be
used to advance medical imaging techniques, enable drug discovery and non-biomedical
applications. Possible biomedical applications include:
• Multifunctional, sequential, real-time imaging and payload delivery to targeted cells.
Enables temporally-controlled drug delivery to treat or eradicate targeted cells, including
cancer, pathogenic and other cell types in vivo and in-vitro.
• Real-time imaging of targeted cells and induced activation of resonant structures to
impart energies to targeted cells. Enables temporally-controlled, non-pharmaceutical
way to treat or eradicate targeted cells.
• Serving as a new class of contrasting agents for cell-targeted medical diagnostic
imaging.
• Improving molecular imaging applications for diagnoses, staging, and treatment of
disease and improving the accuracy and effectiveness of treatments and surgical
techniques, including non-invasive surgeries.
• Serving as a new class of non-fluorescent tags to function as or be used in conjunction
with molecular probes/biomarkers. Possible applications include micro-array and other
research and discovery technologies.
Competitive Advantages
Resonant nanostructures are an enabling technology. Their potential scope of application is
broad. To protect the intellectual property rights to this technology, Mr. Wait filed provisional and
formal patent applications in 2005 and 2006. The patents are currently in review. We believe
RNS technology is unique and non-obvious, and we intend to file additional patents and develop
trade secrets as RNSs are realized and reduced to practice.
Endophore expects to be the first-to-market with this technology and intends to keep this
competitive advantage as the technical landscape and market needs change.

2. June 01, 2007
Endophore Confidential
Page 2 of 2
Financial Requirements
To meet our early goals, Endophore is seeking seed funding of $500K for the first year of
operation. Our near-term goals are to develop first-order calculations and simulations of RNSs
as a proof of concept and to determine initial design parameters, including resonant tune-ability,
in vivo damping effects, and activation frequencies. Based on the modeling results, the
company will begin fabrication of early prototypes and characterize their properties. Next, we
will begin in vitro studies, followed by small animal studies to prove RNS efficacy in vivo. For the
prototype fabrication phase, we intend to work at a no-cost facility such as the LBL Molecular
Foundry and so our animal studies at an academic animal facility.
Management Team
Brad Wait founded Endophore, Inc. in May 2007 and currently serves as the principle inventor
and interim CEO. Brad is a graduate of Stanford University receiving a B.S. with honors and
M.S. in Biological Sciences, and an M.S. in Electrical Engineering. Working primarily in high-
technology, Mr. Wait has over 22 years experience in software and hardware industries working
as a program/project manager, project lead, technical documentation manager, and technical
writer. He has demonstrated proficiency in leading diverse and geographically-distributed teams
working on complex projects.
Consultants, Advisors, and Legal
Brad has assembled a small team of consultants, scientific advisors, and attorney. With the
exception of attorneys, these are currently informal, unofficial relationships.
Consultants
• Tom Chou, Ph.D. Mathematics- Associate Professor, Biomath/Math UCLA Department
of Mathematics. Areas of expertise: mathematical modeling of microscopic and cellular
level biology.
• Natalia Malkova, Ph.D. Solid-State Physics – NIST. Areas of expertise: mathematical
modeling of photonic crystals.
Scientific Advisors
• Robert S. Langer, Ph.D. Chemical Engineering; Institute Professor MIT. Areas of
expertise: drug delivery, biotechnology, immobilized enzymes, biomedical engineering,
biomaterials, tissue engineering.
• Petar Atanackovic, Ph.D. Quantum Electronics - CEO/CTO Translucent Inc... Areas of
expertise: photonics, advanced microfabrication techniques.
Legal Team
• Chinh Pham, of counsel at Greenberg Traurig. Serves as Chair of the Nanotechnology
Practice of the Intellectual Property Department.
• Curtis Mo, Partner at WilmerHale. Recognized as a leading corporate and securities
lawyer in Silicon Valley.
Contact
1 415 640-3063
brad.wait@endophore.com